Chapter 1. Research Framework
1.1. Objective
1.2. Product Overview
1.2.1. Market Segmentation
1.2.2. Market & Segment Definitions
1.3. Research Methodology
1.3.1. List of Primary & Secondary Sources
1.3.2. Market Size Estimation
1.3.2.1. Assumption for the Study
1.3.2.2. Data Triangulation
2.4 Assumption for the Study
2.5 Market Size Estimation
Chapter 2. Executive Summary: Global Chemotherapy Induced Peripheral Neuropathy Treatment Market
Chapter 3. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Overview
3.1. Industry Value Chain Analysis
3.1.1. Raw Material Provider
3.1.2. Manufacturing
3.1.3. Packaging and Distribution
3.1.4. End Users
3.2. PESTLE Analysis
3.3. Porter's Five Forces Analysis
3.3.1. Bargaining Power of Suppliers
3.3.2. Bargaining Power of Buyers
3.3.3. Threat of Substitutes
3.3.4. Threat of New Entrants
3.3.5. Degree of Competition
3.4. Market Dynamics and Trends
3.4.1. Growth Drivers
3.4.2. Restraints
3.4.3. Challenges
3.4.4. Key Trends
3.5. Covid-19 Impact Assessment on Market Growth Trend
3.6. Market Growth and Outlook
3.6.1. Market Revenue Estimates and Forecast (US$ Mn), 2017 2027
3.6.2. Pricing Analysis
3.6.2.1. Price by Manufacturers
3.7. Industry Outlook
3.8. Competition Dashboard
3.8.1. Market Concentration Rate
3.8.1.1. Global CR3, CR10 Ratio in 2020
3.8.2. Company Market Share Analysis (Value %), 2020
3.8.3. Competitor Mapping
Chapter 4. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Analysis, By Type
4.1. Key Insights
4.2. Market Size and Forecast, 2017 - 2027 (US$ Mn)
4.2.1. Calcium Channel ?2-delta Ligands
4.2.2. Antidepressants
4.2.3. Opioids
4.2.4. Others
Chapter 5. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Analysis, By Application
5.1. Key Insights
5.2. Market Size and Forecast, 2017 - 2027 (US$ Mn)
5.2.1. Platinum Agents
5.2.2. Taxanes
5.2.3. Vinca Alkaloids
5.2.4. Others
Chapter 6. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Analysis, By Region/Country
6.1. Key Insights
6.2. Market Size and Forecast, 2017 - 2027 (US$ Mn)
6.2.1. North America
6.2.1.1. The U.S.
6.2.1.2. Canada
6.2.1.3. Mexico
6.2.2. Europe
6.2.2.1. Western Europe
6.2.2.1.1. The UK
6.2.2.1.2. Germany
6.2.2.1.3. France
6.2.2.1.4. Italy
6.2.2.1.5. Spain
6.2.2.1.6. Rest of Western Europe
6.2.2.2. Eastern Europe
6.2.2.2.1. Poland
6.2.2.2.2. Russia
6.2.2.2.3. Rest of Eastern Europe
6.2.3. Asia Pacific
6.2.3.1. China
6.2.3.2. India
6.2.3.3. Japan
6.2.3.4. Australia & New Zealand
6.2.3.5. ASEAN
6.2.3.6. Rest of Asia Pacific
6.2.4. Middle East & Africa (MEA)
6.2.4.1. UAE
6.2.4.2. Saudi Arabia
6.2.4.3. South Africa
6.2.4.4. Rest of MEA
6.2.5. South America
6.2.5.1. Brazil
6.2.5.2. Argentina
6.2.5.3. Rest of South America
Chapter 7. North America Chemotherapy Induced Peripheral Neuropathy Treatment Market Analysis
7.1. Key Insights
7.2. Market Size and Forecast, 2017 - 2027 (US$ Mn)
7.2.1. By Type
7.2.2. By Application
7.2.3. By Country
Chapter 8. US Chemotherapy Induced Peripheral Neuropathy Treatment Market Analysis
8.1. Key Insights
8.2. Market Size and Forecast, 2017 2027 (US$ Mn)
8.2.1. By Type
8.2.2. By Application
8.2.3. By Country
Chapter 9. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market Analysis
9.1. Key Insights
9.2. Market Size and Forecast, 2017 2027 (US$ Mn)
9.2.1. By Type
9.2.2. By Application
9.2.3. By Country
Chapter 10. Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market Analysis
10.1. Key Insights
10.2. Market Size and Forecast, 2017 2027 (US$ Mn)
10.2.1. By Type
10.2.2. By Application
10.2.3. By Country
Chapter 11. Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market Analysis
11.1. Key Insights
11.2. Market Size and Forecast, 2017 2027 (US$ Mn)
11.2.1. By Type
11.2.2. By Application
11.2.3. By Country
Chapter 12. South America Chemotherapy Induced Peripheral Neuropathy Treatment Market Analysis
12.1. Key Insights
12.2. Market Size and Forecast, 2017 2027 (US$ Mn)
12.2.1. By Type
12.2.2. By Application
12.2.3. By Country
Chapter 13. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)
13.1. Aptinyx Inc
13.2. Asahi Kasei Pharma Corp
13.3. Regenacy Pharmaceuticals
13.4. MAKScientific LLC
13.5. Metys Pharmaceuticals AG
13.6. Nemus Bioscience Inc
13.7. PledPharma
13.8. Sova Pharmaceuticals Inc
13.9. DermaXon LLC
13.10. Kineta Inc
13.11. PeriphaGen
13.12. Apexian Pharma
13.13. WinSanTor